- Home
- ROIV vs LW Comparison
ROIV vs LW Comparison
Compare ROIV & LW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | LW |
|---|---|---|
| Founded | 2014 | 1950 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 8.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ROIV | LW |
|---|---|---|
| Price | $21.70 | $42.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | $24.31 | ★ $56.14 |
| AVG Volume (30 Days) | ★ 8.2M | 3.2M |
| Earning Date | 02-09-2026 | 12-19-2025 |
| Dividend Yield | N/A | ★ 3.62% |
| EPS Growth | N/A | ★ 9.13 |
| EPS | N/A | ★ 2.78 |
| Revenue | $20,329,000.00 | ★ $6,473,600,000.00 |
| Revenue This Year | N/A | $4.13 |
| Revenue Next Year | $741.42 | N/A |
| P/E Ratio | ★ N/A | $15.11 |
| Revenue Growth | N/A | ★ 2.35 |
| 52 Week Low | $8.73 | $41.41 |
| 52 Week High | $23.47 | $67.93 |
Technical Indicators
Market Signals| Indicator | ROIV | LW |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 18.69 |
| Support Level | $21.36 | $41.42 |
| Resistance Level | $22.72 | $42.84 |
| Average True Range (ATR) | 0.80 | 1.63 |
| MACD | -0.13 | -1.36 |
| Stochastic Oscillator | 45.71 | 3.24 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About LW Lamb Weston Holdings Inc.
Lamb Weston is North America's largest and the world's second-largest producer of branded and private-label frozen potato products, both by volume and value. The company's portfolio is anchored by french fries, but it also sells sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. Roughly two thirds of revenue comes from its home market of North America, with none of the other 100 countries the company sells into representing a significant share. McDonald's is Lamb Weston's single-largest customer at 15% of fiscal 2025 sales, with no other company representing more than 10%. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.